<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01715415</url>
  </required_header>
  <id_info>
    <org_study_id>M13-098</org_study_id>
    <secondary_id>2012-002035-29</secondary_id>
    <nct_id>NCT01715415</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Afssaps - Agence francaise de securite sanitaire des produits de sante (Saint-Denis)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and
      ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as
      dasabuvir) co-administered with ribavirin (RBV) in hepatitis C virus genotype 1 infected
      treatment-experienced adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment</measure>
    <time_frame>12 weeks after the last actual dose of active study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [&lt; LLOQ]) 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period</measure>
    <time_frame>At 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment</measure>
    <time_frame>12 weeks after the last actual dose of active study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [&lt; LLOQ]) 12 weeks after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment</measure>
    <time_frame>12 weeks after the last actual dose of active study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [&lt; LLOQ]) 12 weeks after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm</measure>
    <time_frame>12 weeks after the last actual dose of active study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid [HCV RNA] ≥ lower limit of quantification [LLOQ] after HCV RNA &lt; LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm</measure>
    <time_frame>Within 12 weeks post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA &lt; LLOQ at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/r/ABT-267, ABT-333</intervention_name>
    <description>Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet</description>
    <arm_group_label>ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
    <arm_group_label>Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
    <other_name>ABT-267 also known as ombitasvir</other_name>
    <other_name>ABT-450 also known as paritaprevir</other_name>
    <other_name>ABT-333 also known as dasabuvir</other_name>
    <other_name>Viekira PAK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Capsule (double-blind treatment period), tablet (open-label treatment period)</description>
    <arm_group_label>ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
    <arm_group_label>Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABT-450/r/ABT-267</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABT-333</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ribavirin</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females must be post-menopausal for at least 2 years or surgically sterile or
             practicing specific forms of birth control.

          -  Chronic hepatitis C, genotype 1 infection and HCV RNA level greater than 10,000 IU/mL
             at screening.

          -  Previous treatment failure of peg-interferon and ribavirin (pegIFN and RBV).

          -  No evidence of liver cirrhosis.

        Exclusion Criteria:

          -  Positive screen for drugs or alcohol.

          -  Significant sensitivity to any drug.

          -  Use of contraindicated medications within 2 weeks of dosing.

          -  Certain predefined abnormal laboratory tests.

          -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Enejosa, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 23, 2015</lastchanged_date>
  <firstreceived_date>October 25, 2012</firstreceived_date>
  <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Treatment-Experienced</keyword>
  <keyword>Null responder</keyword>
  <keyword>Partial Responder</keyword>
  <keyword>Chronic Hepatitis</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Interferon-Free</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Relapser</keyword>
  <keyword>Non responder</keyword>
  <keyword>Viekira Pak</keyword>
  <keyword>ombitasvir</keyword>
  <keyword>ribavirin</keyword>
  <keyword>ritonavir</keyword>
  <keyword>paritaprevir</keyword>
  <keyword>dasabuvir</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
